A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Canagliflozin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Corporation
- 15 Sep 2017 Results assessing the long-term efficacy and safety of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes, were presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 13 Jun 2017 Long-term safety and efficacy results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 21 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.